High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective
- 15 February 2008
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 48 (5) , 792-800
- https://doi.org/10.1016/j.jhep.2007.12.023
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Nuclear Translocation of UDCA by the Glucocorticoid Receptor Is Required to Reduce TGF-β1–Induced Apoptosis in Rat Hepatocytes *Hepatology, 2005
- Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitisHepatology, 2004
- Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways†Hepatology, 2004
- Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytesHepatology, 2002
- The Relative Role of the Child–Pugh Classification and the Mayo Natural History Model in the Assessment of Survival in Patients With Primary Sclerosing CholangitisHepatology, 1999
- Ursodiol for Primary Sclerosing CholangitisNew England Journal of Medicine, 1997
- Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study periodJournal of Hepatology, 1994
- Ursodeoxycholic acid for primary sclerosing cholangitisJournal of Hepatology, 1990
- Primary Sclerosing Cholangitis: A Long-Term Follow-up StudyScandinavian Journal of Gastroenterology, 1987
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981